# Flatiron Health

Flatiron Health is an other based in New York, United States.

## Overview

- **Organization type:** other
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** flatiron.com
- **LinkedIn:** https://www.linkedin.com/company/flatiron-health

## Regulatory record

- **Reports private funds:** No

## About

Flatiron Health provides an oncology data, intelligence, and technology platform that combines AI-powered technology with deep clinical expertise. Its global oncology engine is built on one of the world’s largest oncology datasets across the US, UK, Germany, and Japan, alongside point of care technology used by community oncologists. The company helps thousands of providers and life science organizations generate insights and improve outcomes for people living with cancer.

## Sectors

- Digital Health
- Healthcare Services
- AI/ML

## Offices

- Menlo Park, CA, United States
- Lakeland, FL, United States

## People

- Nat Turner — Co-Founder
- Zach Weinberg — Co-Founder

## Questions

### Who runs investment decisions at Flatiron Health?

Flatiron Health is a wholly owned subsidiary of Roche. Its CEO as of 2025 is Caroline Pavis, who succeeded founder Nat Turner in 2021. Investment in the platform and product development decisions are made by Flatiron's executive team, which includes a chief medical officer, chief technology officer, and chief commercial officer. Roche's diagnostics division holds strategic oversight but delegates daily operational control.

### How does Flatiron Health source proprietary data?

Flatiron Health sources clinical data through a network of over 280 community and academic oncology practices that use its electronic health record (EHR) software, Flatiron OncoEMR. Data is ingested in near real-time via direct EHR integration. The company also partners with genomic testing labs and claims data providers to enrich its dataset. All data is de-identified and used under patient consent and HIPAA-compliant protocols.

### What investment stages does Flatiron Health typically target?

Flatiron Health does not make investments. As a commercial entity, its stage focus is on scaling adoption among oncology practices and life sciences clients. Its product development targets later-stage clinical trial support — Phase III and post-market — but its data network also supports early-stage research such as biomarker discovery and trial site selection.

### Which sectors does Flatiron Health explicitly avoid?

Flatiron Health avoids any therapeutic area outside oncology. It does not build or license EHRs for non-cancer specialties. The company also avoids direct patient-facing applications, such as telemedicine or consumer health apps, and does not operate in the insurance or payer market. Its data licensing agreements specifically exclude use in insurance underwriting or risk-scoring.

### How is Flatiron Health related to its parent company, Roche?

Flatiron Health is a wholly owned subsidiary of Roche, acquired in 2018 for $1.9B (per Roche, 2018). Roche's diagnostics division owns the company. Flatiron operates as an independent subsidiary with its own board, executive team, and P&L. Roche uses Flatiron's data platform to accelerate drug development and co-markets Flatiron's EHR to oncology clinics through its global commercial network. The two entities share no commingled funds or investment vehicles.

## Related profiles

- [Indeed](https://altss.com/profile/indeed)
- [Hippo](https://altss.com/profile/hippo)

---

Last updated: 2026-07-10T23:32:21.000Z

Canonical page: https://altss.com/profile/flatiron-health

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology